Hypoglycemia is defined as a blood glucose <70 mg/dL (3.9 mmol/L) and is classified into three levels: Level 1 (54–69 mg/dL), Level 2 (<54 mg/dL, neuroglycopenic threshold), and Level 3 (altered mental/physical status requiring third-party assistance). [1-2] Most commonly iatrogenic in patients with diabetes, but spontaneous hypoglycemia in non-diabetic patients warrants a thorough etiologic workup. [3-4]
1. History
- Timing: Fasting vs. postprandial — fasting hypoglycemia suggests insulinoma, adrenal insufficiency, hepatic/renal failure, or medication effect; postprandial suggests reactive hypoglycemia or post-bariatric dumping [3-4]
- Symptom characterization: Adrenergic (tremor, palpitations, diaphoresis, hunger, anxiety) vs. neuroglycopenic (confusion, slurred speech, visual changes, seizure, LOC) [1][5]
- Medication review: Insulin type/dose/timing, sulfonylureas, meglitinides; recent dose changes; accidental overdose or medication errors [1][6]
- Precipitants: Missed meals, increased physical activity, alcohol intake, recent illness, vomiting, reduced oral intake, recent surgery [6-7]
- Frequency and severity: Prior episodes, pattern recognition, ability to self-treat vs. requiring assistance [1]
- Hypoglycemia awareness: "Can you always feel when your blood sugar is low?" — impaired awareness dramatically increases risk for level 3 events [1]
- Important negatives: No weight loss (argues against insulinoma/malignancy), no history of bariatric surgery, no access to insulin or sulfonylureas (factitious) [3][8]
2. Alarm Features
- Level 3 hypoglycemia: Altered mental status, seizures, loss of consciousness, coma [1-2]
- Recurrent unexplained hypoglycemia in a non-diabetic patient (consider insulinoma, adrenal crisis, sepsis) [3-4]
- Refractory hypoglycemia not responding to standard glucose administration (consider sulfonylurea overdose, insulinoma, hepatic failure) [8]
- Focal neurologic deficits mimicking stroke (neuroglycopenia can present as hemiparesis)
- Signs of critical illness: Sepsis, hepatic failure, adrenal crisis, multiorgan dysfunction [3][9]
- Hypoglycemia in a non-diabetic patient without obvious cause — always a red flag requiring workup [3-4]
3. Medications
Common causative agents
- Insulin (most common cause of iatrogenic hypoglycemia) [1][6]
- Sulfonylureas (especially glyburide — long-acting, renally cleared) [1][10]
- Meglitinides (nateglinide, repaglinide) [1]
- Other contributors: beta-blockers (mask symptoms), alcohol, salicylates, quinolones, pentamidine, quinine [9-10]
Treatment medications
- Oral glucose (15 g fast-acting carbohydrate) — preferred first-line for conscious patients [1][11]
- IV dextrose: D50 (25 g/50 mL), D10, or D25 — all equally effective in achieving GCS 15 (median ~6 min); D10 may result in lower total glucose administered [12]
- Glucagon: 1 mg IM/SC/intranasal for unconscious patients; newer formulations include intranasal glucagon and dasiglucagon (no reconstitution needed) [7]
- Caution: Glucagon may be less effective in type 2 diabetes and is relatively contraindicated in sulfonylurea-induced hypoglycemia (stimulates insulin release) [13]
- Patients on acarbose must receive pure glucose (acarbose inhibits sucrose/starch breakdown) [1]
4. Diet
Acute treatment
- 15 g fast-acting glucose (glucose tablets preferred over dietary sugars) → recheck in 15 min → repeat if BG still <70 mg/dL ("Rule of 15") [1][5][11]
- After recovery: 20 g long-acting carbohydrate with protein (e.g., cheese and crackers, peanut butter sandwich) to prevent recurrence [7][11]
- Avoid high-fat foods for initial treatment (slows glucose absorption); avoid protein-only foods (may stimulate insulin) [1]
Long-term management
- Regular meal timing; avoid prolonged fasting
- Pre-exercise carbohydrate loading for insulin-treated patients
- Alcohol moderation — alcohol inhibits gluconeogenesis and can cause delayed hypoglycemia
- For reactive/postprandial hypoglycemia: smaller, more frequent meals with complex carbohydrates and protein; avoid high-glycemic-index foods
5. Review of Systems
- Neurologic: Confusion, dizziness, visual changes, seizures, focal deficits, LOC
- Cardiovascular: Palpitations, tachycardia, chest pain (catecholamine surge)
- Psychiatric: Anxiety, irritability, behavioral changes (can mimic intoxication or psychiatric illness) [14]
- GI: Nausea, hunger, abdominal pain (consider adrenal insufficiency)
- Endocrine: Weight changes, heat/cold intolerance, skin hyperpigmentation (Addison's), galactorrhea (pituitary)
- Constitutional: Fatigue, diaphoresis, weakness
6. Collateral History and Family History
- Collateral: Witnessed events, duration of altered consciousness, medication access (factitious hypoglycemia), alcohol use, recent dietary changes [8][10]
- Family history: Diabetes, MEN-1 syndrome (insulinoma association), congenital hyperinsulinism, glycogen storage diseases, adrenal insufficiency [9-10]
- Social context: Access to medications (insulin, sulfonylureas), intentional overdose risk, occupational hazards (driving, operating machinery), food insecurity [1]
7. Risk Factors
- Insulin, sulfonylurea, or meglitinide use (primary risk factor) [1]
- Prior hypoglycemic episodes — strongest predictor of recurrence [1]
- Impaired hypoglycemia awareness (hypoglycemia-associated autonomic failure) [1]
- Chronic kidney disease (decreased insulin clearance) [1][6]
- Hepatic failure (impaired gluconeogenesis/glycogenolysis) [3][6]
- Older age, cognitive impairment [1]
- Sepsis and critical illness [3][6]
- Alcohol use [11]
- Malnutrition, reduced oral intake, gastroparesis [1][6]
- Post-bariatric surgery (dumping physiology) [3][10]
- Adrenal insufficiency, hypopituitarism [3][8]
- Female sex (independent risk factor, mechanism unclear) [1]
8. Differential Diagnosis
In diabetic patients
- Medication-related (insulin, sulfonylurea overdose/error, timing mismatch with meals)
- Reduced renal/hepatic clearance of glucose-lowering agents
- Adrenal insufficiency (co-existing)
In non-diabetic patients — cannot-miss diagnoses
- Insulinoma — fasting hypoglycemia with endogenous hyperinsulinism [3-4][8]
- Adrenal crisis — hypoglycemia + hypotension + hyperkalemia
- Sepsis — hypoglycemia as marker of critical illness [3]
- Factitious hypoglycemia — surreptitious insulin or sulfonylurea use [8][10]
- Non-islet cell tumor (e.g., large mesenchymal tumors producing IGF-II) [4][8]
Other considerations
- Post-bariatric (post-gastric bypass) hypoglycemia [3][10]
- Reactive/postprandial hypoglycemia
- Autoimmune insulin syndrome (Hirata disease) [4]
- Hepatic failure, renal failure [3]
- Hormonal deficiency (cortisol, growth hormone) [3][8]
- Inherited metabolic disorders (glycogen storage diseases, fatty acid oxidation defects) [9]
- Alcohol-induced hypoglycemia
9. Past Medical History
- Diabetes type and duration, current regimen, A1C
- Prior hypoglycemic episodes — frequency, severity, precipitants [1]
- CKD/liver disease (altered drug metabolism) [6]
- Bariatric surgery history [3][10]
- Adrenal/pituitary disease
- Malignancy (non-islet cell tumors)
- Psychiatric history (factitious disorder, intentional overdose)
- Cardiac disease (hypoglycemia associated with increased CV mortality) [1]
10. Physical Exam
Vital signs
- Tachycardia, diaphoresis (adrenergic response)
- Hypotension (consider adrenal insufficiency, sepsis)
- Hypothermia (severe/prolonged hypoglycemia)
Focused exam
- Neuro: Mental status (GCS), focal deficits (neuroglycopenia can mimic stroke), tremor, seizure activity
- Skin: Diaphoresis, pallor; hyperpigmentation (Addison's); injection sites (insulin use/abuse)
- Abdomen: Hepatomegaly (liver disease, glycogen storage disease) [10]
- Endocrine stigmata: Cushingoid features (recent steroid taper), signs of hypopituitarism
11. Lab Studies
Immediate
- Point-of-care glucose (confirm hypoglycemia before and during treatment)
- BMP (renal function, electrolytes, anion gap)
- Hepatic panel (liver failure assessment)
Critical sample (draw at time of hypoglycemia, before treatment if possible): [8][10]
- Plasma glucose, insulin, C-peptide, proinsulin
- Beta-hydroxybutyrate (suppressed in hyperinsulinism)
- Sulfonylurea/meglitinide screen (urine and plasma)
- Cortisol (if adrenal insufficiency suspected)
Interpretation pearls
- High insulin + high C-peptide = endogenous hyperinsulinism (insulinoma, sulfonylurea) [8][15]
- High insulin + low C-peptide = exogenous insulin administration (factitious) [10]
- Positive sulfonylurea screen = drug-induced [8]
- Suppressed beta-hydroxybutyrate and FFA = inappropriate insulin action [10]
Additional labs as indicated: CBC, lactate, cortisol, ACTH, IGF-II, insulin antibodies, A1C [3][8]
12. Imaging
- Not routinely indicated in the ED for straightforward medication-related hypoglycemia
- CT abdomen/pelvis or MRI pancreas: If insulinoma suspected (after biochemical confirmation of endogenous hyperinsulinism) [8]
- Endoscopic ultrasound: Most sensitive for localizing pancreatic insulinomas [8]
- CT head: Consider if persistent altered mental status after glucose correction (rule out stroke, intracranial pathology)
- 68Ga-DOTATATE PET/CT: For occult insulinoma not seen on conventional imaging
13. Special Tests
- Whipple's triad — must be confirmed before pursuing extensive workup in non-diabetic patients: (1) symptoms consistent with hypoglycemia, (2) documented low glucose, (3) resolution with glucose correction [3-4][8]
- 72-hour supervised fast: Gold standard provocative test for fasting hypoglycemia (insulinoma workup) [4][8]
- Mixed-meal tolerance test: For postprandial/reactive hypoglycemia [4][8]
- Glucagon stimulation test: Glycemic rise >30 mg/dL is nearly pathognomonic of hyperinsulinism [10]
- ACTH stimulation test: If adrenal insufficiency suspected [10]
- Hypoglycemia awareness screening tools: Gold score, Clarke questionnaire [1]
14. ECG
- Indications: Obtain in patients with chest pain, palpitations, syncope, or known cardiac disease
- Expected findings: Sinus tachycardia (catecholamine surge)
- Dangerous patterns: QTc prolongation (hypoglycemia can prolong QT interval and trigger arrhythmias), ST changes (demand ischemia in patients with CAD), atrial/ventricular arrhythmias
- Hypoglycemia is an independent risk factor for cardiovascular events and arrhythmias in diabetic patients [1]
15. Assessment
Severity classification (ADA 2026): [1]
- Most hypoglycemia in clinical practice is iatrogenic in diabetic patients on insulin or secretagogues [4][7]
- Spontaneous hypoglycemia in a non-diabetic, apparently well adult is uncommon and warrants systematic evaluation [3-4]
- Hypoglycemia in hospitalized patients is a marker of underlying disease severity and is independently associated with increased mortality [1][6]
16. Treatment Plan
Immediate stabilization
- Conscious patient: 15 g oral glucose (glucose tablets preferred) → recheck BG in 15 min → repeat until BG >70 mg/dL → follow with protein/carb snack [1][11]
- Unconscious/unable to swallow:
- IV access: D50W 25 g (50 mL) IV push, or D10W in 5 g aliquots (equally effective, may reduce overshoot) [12]
- No IV access: Glucagon 1 mg IM/SC or intranasal glucagon 3 mg [7]
- Sulfonylurea-induced hypoglycemia: Anticipate prolonged/recurrent hypoglycemia — start D10W continuous infusion, consider octreotide 50–100 mcg SC q6–8h (inhibits insulin secretion; key pearl for sulfonylurea overdose)
- After stabilization: identify and address the precipitant (medication error, missed meal, renal decline, etc.) [1][6]
Medication adjustments
- Level 2 or 3 events should prompt reevaluation and deintensification of the diabetes regimen [1]
- Prescribe glucagon for all insulin-treated patients and those at high risk [1]
- Consider CGM for patients with recurrent hypoglycemia or impaired awareness [1]
The following figure illustrates a treatment algorithm for acute hypoglycemia management:
17. Disposition
Admit/observe if
- Sulfonylurea or long-acting insulin overdose (risk of prolonged/recurrent hypoglycemia — observe minimum 12–24 hours) [7]
- Level 3 hypoglycemia with prolonged altered mental status [7]
- Recurrent hypoglycemia despite treatment
- Unexplained hypoglycemia in a non-diabetic patient requiring workup [3]
- Underlying critical illness (sepsis, hepatic failure, adrenal crisis)
- Intentional overdose (psychiatric evaluation needed)
Discharge if
- Rapid response to treatment with return to baseline mental status
- Clear, correctable precipitant identified (e.g., missed meal with short-acting insulin)
- Reliable follow-up and ability to self-monitor
- Adequate education on hypoglycemia recognition and treatment
- Glucagon prescribed and caregiver education provided [1]
18. Follow Up / Return Precautions
Follow-up timing
- PCP or endocrinology within 1–3 days after ED visit for level 2/3 hypoglycemia to review and adjust the diabetes regimen [1][16]
- Endocrinology referral for unexplained spontaneous hypoglycemia in non-diabetic patients [3][8]
Return precautions — instruct patients to return immediately for:
- Recurrent symptoms of hypoglycemia (shakiness, sweating, confusion)
- Inability to keep food/fluids down
- Seizure, loss of consciousness, or confusion
- BG persistently <70 mg/dL despite treatment
Patient counseling
- Carry glucose tablets at all times; ensure glucagon is accessible to caregivers [1]
- Do not drive or operate machinery if symptomatic
- Screen for and address impaired hypoglycemia awareness — several weeks of strict hypoglycemia avoidance can partially restore awareness [1]
- Review the "Rule of 15" for self-treatment [1][11]
- Educate on medication timing relative to meals and exercise
References
1. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. — American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care. 2026.
2. Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline. — McCall AL, Lieb DC, Gianchandani R, et al. The Journal of Clinical Endocrinology and Metabolism. 2023.
3. Clinical Presentation and Diagnostic Approach to Hypoglycemia in Adults Without Diabetes Mellitus. — Palani G, Stortz E, Moheet A. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2023.
4. MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and Management of Hypoglycemia. — Kittah NE, Vella A. European Journal of Endocrinology. 2017.
5. 2024 American Heart Association and American Red Cross Guidelines for First Aid. — Hewett Brumberg EK, Douma MJ, Alibertis K, et al. Circulation. 2024.
6. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2026. — American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care. 2026.
7. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. — Blonde L, Umpierrez GE, Reddy SS, et al. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2022.
8. Spontaneous Hypoglycemia: Diagnostic Evaluation and Management. — Kandaswamy L, Raghavan R, Pappachan JM. Endocrine. 2016.
9. Hypoglycaemia Related to Inherited Metabolic Diseases in Adults. — Douillard C, Mention K, Dobbelaere D, et al. Orphanet Journal of Rare Diseases. 2012.
10. Recommendations From the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. — Thornton PS, Stanley CA, De Leon DD, et al. The Journal of Pediatrics. 2015.
11. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). — Holt RIG, DeVries JH, Hess-Fischl A, et al. Diabetes Care. 2021.
12. Efficacy of 10%,25% and 50% Dextrose in the Treatment of Hypoglycemia in the Emergency Department - A Randomized Controlled Study. — Verma A, Jaiswal S, Reid C, et al. The American Journal of Emergency Medicine. 2024.
13. Hypoglycaemia. — Iskandar Idris, Rudy Bilous, Richard Donnelly Handbook of Diabetes 5e. 2021.
14. Diabetes Management in Detention Facilities: A Statement of the American Diabetes Association. — Lorber DL, ElSayed NA, Bannuru RR, et al. Diabetes Care. 2024.
15. Approach to the Patient With Spontaneous Hypoglycemia. — Martens P, Tits J. European Journal of Internal Medicine. 2014.
16. Assessment and Prevention of Hypoglycaemia in Primary Care Among U.S. Veterans: A Mixed Methods Study. — Pilla SJ, Meza KA, Beach MC, et al. Lancet Regional Health. Americas. 2023.